Abstract:What's new? Resistance to targeted and immune therapies limits the benefits of current treatments in melanoma. This study provides evidence for a new combined approach in targeting BRAF inhibitor‐resistant melanoma. Pharmacological inhibition of the resistance‐inducing Rho/MRTF pathway using CCG‐257081 enhanced the response to PD1/PDL1 blockade in vivo. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophage infiltration. CCG‐257081 emerges as a potential new anti‐resistance agent that can improve the response to immune checkpoint inhibitors in advanced melanoma. Metastatic cutaneous melanoma is a fatal skin cancer. Resistance to targeted and immune therapies limits the benefits of current treatments. Identifying and adding anti‐resistance agents to current treatment protocols can potentially improve clinical responses. Myocardin‐related transcription factor (MRTF) is a transcriptional coactivator whose activity is indirectly regulated by actin and the Rho family of GTPases. We previously demonstrated that development of BRAF inhibitor (BRAFi) resistance frequently activates the Rho/MRTF pathway in human and mouse BRAFV600E melanomas. In clinical trials, pretreatment with BRAFi reduces the benefit of immune therapies. We aimed to test the efficacy of concurrent treatment with our MRTF pathway inhibitor CCG‐257081 and anti‐PD1 in vivo and to examine its effects on the melanoma immune microenvironment. Because MRTF pathway activation upregulates the expression of immune checkpoint inhibitor genes/proteins, we asked whether CCG‐257081 can improve the response to immune checkpoint blockade. CCG‐257081 reduced the expression of PDL1 in BRAFi‐resistant melanoma cells and decreased surface PDL1 levels on both BRAFi‐sensitive and ‐resistant melanoma cells. Using our recently described murine vemurafenib‐resistant melanoma model, we found that CCG‐257081, in combination with anti‐PD1 immune therapy, reduced tumor growth and increased survival. Moreover, anti‐PD1/CCG‐257081 co‐treatment increased infiltration of CD8+ T cells and B cells into the tumor microenvironment and reduced tumor‐associated macrophages. Here, we propose CCG‐257081 as an anti‐resistance and immune therapy‐enhancing anti‐melanoma agent.

Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages

Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1

Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Preclinical Pharmacokinetics, Biodistribution, and Acute Toxicity Evaluation of Caerin 1.9 Peptide in Sprague Dawley Rats

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment

Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME

Reprogramming of Cancer-Associated Fibroblasts Combined with Immune Checkpoint Inhibitors: A Potential Therapeutic Strategy for Cancers.

Inhibition of the Rho/MRTF pathway improves the response of BRAF‐resistant melanoma to PD1/PDL1 blockade

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity

Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Synergistic immunotherapy with a calcium-based nanoinducer: evoking pyroptosis and remodeling tumor-associated macrophages for enhanced antitumor immune response

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Inhibition of melanoma by survivin-specific lymphocytes combined with CCL17 and granulocyte-macrophage colony-stimulating factor in a mouse syngeneic model